Stockreport

Protalix BioTherapeutics (PLX): Evaluating Valuation After EMA Setback on Elfabrio Dosing Regimen [Yahoo! Finance]

Protalix BioTherapeutics, Inc. (DE)  (PLX) 
PDF Products for Human Use issued a negative opinion on a proposed less frequent dosing schedule for Elfabrio, its Fabry disease therapy. See our latest analysis for Prota [Read more]